Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BV47
UPID:
DUS26_HUMAN
Alternative names:
Dual specificity phosphatase SKRP3; Low-molecular-mass dual-specificity phosphatase 4; Mitogen-activated protein kinase phosphatase 8; Novel amplified gene in thyroid anaplastic cancer
Alternative UPACC:
Q9BV47; D3DSV8; Q9BTW0
Background:
Dual specificity protein phosphatase 26 (DUSP26), also known as Mitogen-activated protein kinase phosphatase 8, plays a crucial role in cellular processes by inactivating MAPK1 and MAPK3. This action leads to the dephosphorylation of heat shock factor protein 4, reducing its DNA-binding activity. DUSP26 is also involved in inhibiting MAP kinase p38 and preventing apoptosis in anaplastic thyroid cancer cells, alongside its ability to activate MAP kinase p38 and c-Jun N-terminal kinase (JNK).
Therapeutic significance:
Understanding the role of Dual specificity protein phosphatase 26 could open doors to potential therapeutic strategies.